Advertisement

Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy

Published:August 15, 2021DOI:https://doi.org/10.1016/j.clgc.2021.08.001

      Abstract

      Background

      Bipolar androgen therapy (BAT) is an emerging treatment strategy for men with metastatic castration resistant prostate cancer (mCRPC) whereby serum testosterone is cycled from supraphysiologic to near-castrate levels each month. BAT has been shown to induce clinical responses in a significant proportion of patients, some of which are extreme. We explored the clinical and molecular characteristics of patients with mCRPC who achieved deep responses to BAT.

      Methods

      We conducted a retrospective analysis of patients with mCRPC treated with BAT at Johns Hopkins. We identified 22 of 114 (19%) patients with mCRPC who achieved ≥70% PSA reductions upon treatment with BAT. All patients were treated using 400 mg testosterone cypionate intramuscularly every 28 days, together with continuous LHRH agonist therapy. Clinical-grade DNA sequencing was obtained using commercially available assays.

      Results

      Somatic next-generation sequencing was obtained for 15 of 22 (68%) patients. Of these 15 extreme PSA responders with sequencing data available, All 15 of 15 (100%) harbored a pathogenic mutation in TP53 and/or a homologous recombination DNA repair (HRD) gene. Among the subset of patients with measureable disease (N = 15), 10 patients (67%) achieved an objective response including one patient with a complete response. The median radiographic progression-free survival of these deep PSA responders was 11.3 months (95% CI, 7.9-25.0 months).

      Conclusions

      We observed an enrichment of TP53 and HRD mutations in mCRPC patients with extreme PSA responses to BAT, with durability lasting about a year. These data support the hypothesis that BAT may most benefit patients with DNA repair-deficient mCRPC. Further studies of BAT in biomarker-selected mCRPC populations (ie, TP53/HRD-mutated) are warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Denmeade SR
        • Isaacs JT.
        Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
        Prostate. 2010; 70: 1600-1607
        • Schweizer MT
        • Antonarakis ES
        • Wang H
        • et al.
        Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
        Sci Transl Med. 2015; 7 (269ra262)
      1. Schweizer MT, Wang H, Luber B, et al. Bipolar androgen therapy for men with androgen ablation naive prostate cancer: results from the phase II BATMAN study. Prostate.2016;76:1218-1226.

        • Teply BA
        • Wang H
        • Luber B
        • et al.
        Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
        Lancet Oncol. 2018; 19: 76-86
        • Markowski MC
        • Wang H
        • Sullivan R
        • et al.
        A multicohort open-label phase II trial of bipolar androgen therapy in men with metastatic castration-resistant prostate cancer (RESTORE): a comparison of post-abiraterone versus post-enzalutamide cohorts.
        Eur Urol. 2020; 79: 692-699
        • Denmeade SR
        • Wang H
        • Agarwal N
        • et al.
        TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer.
        J Clin Oncol. 2021; 39: 1371-1382
        • Haffner MC
        • Aryee MJ
        • Toubaji A
        • et al.
        Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.
        Nat Genet. 2010; 42: 668-675
        • Bastus NC
        • Boyd LK
        • Mao X
        • et al.
        Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.
        Cancer Res. 2010; 70: 9544-9548
        • Chatterjee P
        • Schweizer MT
        • Lucas JM
        • et al.
        Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
        J Clin Invest. 2019; : 130
        • Lam HM
        • Nguyen HM
        • Labrecque MP
        • et al.
        Durable response of enzalutamide-resistant prostate cancer to supraphysiological testosterone is associated with a multifaceted growth suppression and impaired DNA damage response transcriptomic program in patient-derived xenografts.
        Eur Urol. 2020; 77: 144-155
        • Teply BA
        • Kachhap S
        • Eisenberger MA
        • Denmeade SR.
        Extreme response to high-dose testosterone in BRCA2- and ATM-mutated prostate cancer.
        Eur Urol. 2017; 71: 499
        • Litvinov IV
        • Vander Griend DJ
        • Antony L
        • et al.
        Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.
        Proc Natl Acad Sci. 2006; 103 (U S A): 15085-15090
        • Vander Griend DJ
        • Litvinov IV
        • Isaacs JT.
        Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation.
        Cell Cycle. 2007; 6: 647-651
        • Mateo J
        • Carreira S
        • Sandhu S
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Zhao B
        • Lin J
        • Rong L
        • et al.
        ARID1A promotes genomic stability through protecting telomere cohesion.
        Nat Commun. 2019; 10: 4067
        • Shen J
        • Peng Y
        • Wei L
        • et al.
        ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors.
        Cancer Discov. 2015; 5: 752-767
        • Kastan MB
        • Onyekwere O
        • Sidransky D
        • Vogelstein B
        • Craig RW.
        Participation of p53 protein in the cellular response to DNA damage.
        Cancer Res. 1991; 51: 6304-6311
        • Maughan BL
        • Guedes LB
        • Boucher K
        • et al.
        p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
        Prostate Cancer Prostatic Dis. 2018; 21: 260-268
        • Aparicio AM
        • Shen L
        • Tapia EL
        • et al.
        Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers.
        Clin Cancer Res. 2016; 22: 1520-1530
        • Abida W
        • Cyrta J
        • Heller G
        • et al.
        Genomic correlates of clinical outcome in advanced prostate cancer.
        Proc Natl Acad Sci U S A. 2019; 116: 11428-11436
        • Cerami E
        • Gao J
        • Dogrusoz U
        • et al.
        The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
        Cancer Discov. 2012; 2: 401-404

      CHORUS Manuscript

      View Open Manuscript